Omnipod is in the news this week!
Insulet Corporation S hareholder Broadcast reported that Insulet presented strong Omnipod Horizon Hybrid Closed-Loop study results on 16 February 2017 at the 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France. The study demonstrated that the Omnipod automated glucose control algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose.
Study participants included 24 adults with type 1 diabetes. The 36-hour study1 included a modified version of Insulet’s Omnipod, a Dexcom® continuous glucose sensor, and Insulet’s personalized model predictive control algorithm. Results showed use of the Company’s hybrid closed-loop system was associated with significantly less time spent in hypoglycemic blood glucose range compared to ranges prior to the study. Key findings included patients achieving and remaining in the target blood glucose control range 69% of the time over the course of the study and maintaining target blood glucose control 90% of the time during the overnight period.
“These very positive results, particularly in the overnight period, demonstrate the potential for the Omnipod Horizon System to improve clinical outcomes in patients with type 1 diabetes,” said Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter Packard Children’s Hospital, Stanford University, and Principal Investigator of the study. “This is a safe system providing significant reductions in hypoglycemia both during the day and night, and the system made significant improvements in overnight glucose control, decreasing glucose variability and bringing fasting glucose values into range. These are very positive early findings and I think I speak for the entire team when I say I am excited to see how the Horizon system continues to perform in future clinical studies.”
AND … Insulet Corporation acquired a U.S. manufacturing facility in Acton, Massachusetts, to establish a manufacturing location in the United States.
The state-of-the-art facility, when outfitted with highly-automated manufacturing equipment, will provide capacity for Insulet to manufacture on a single line up to 70 percent more pods with up to 90 percent fewer headcount as compared to all four of the Company’s current manufacturing lines at its contract manufacturer in China. Insulet will begin build-out of the facility and expects to begin production in 2019. The Company anticipates the addition of hundreds of jobs in Massachusetts over the next five years.
“This acquisition marks a major milestone in the execution of our strategic plan to expand pod manufacturing, increase productivity, improve quality and drive efficiency,” said Patrick Sullivan, Chairman and Chief Executive Officer. “The addition of U.S. production capabilities will improve our response time to customers. This will be a significant improvement to our manufacturing operations.”
